Certolizumab Pegol

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Axial Spondyloarthrithis

Conditions

Axial Spondyloarthrithis, Ankylosing Spondylitis

Trial Timeline

Jul 1, 2015 → Apr 1, 2019

NCT ID

NCT02505542

About Certolizumab Pegol

Certolizumab Pegol is a phase 3 stage product being developed by UCB for Axial Spondyloarthrithis. The current trial status is completed. This product is registered under clinical trial identifier NCT02505542. Target conditions include Axial Spondyloarthrithis, Ankylosing Spondylitis.

What happened to similar drugs?

6 of 20 similar drugs in Axial Spondyloarthrithis were approved

Approved (6) Terminated (1) Active (14)

🔄Brodalumab + PlaceboKyowa KirinPhase 3

🔄Ixekizumab + PlaceboEli LillyPhase 3

🔄SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3

✅AdalimumabAbbVieApproved

🔄Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3

🔄adalimumab + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03559686	Pre-clinical	Active	—	—	Rheumatoid Arthritis
NCT03559660	Pre-clinical	Completed	—	—	Crohn's Disease
NCT04740814	Phase 1	Completed	Feb 11, 2021	Jun 27, 2022	Rheumatoid Arthritis
NCT04053881	Pre-clinical	Completed	Aug 21, 2019	Dec 2, 2022	Plaque Psoriasis
NCT03051217	Phase 2/3	Completed	Feb 21, 2017	Jan 16, 2019	Moderate to Severe Psoriasis
NCT03020992	Approved	Completed	Dec 21, 2016	Jan 23, 2020	Axial Spondyloarthritis (axSpA)
NCT02597829	Approved	UNKNOWN	Nov 1, 2015	Oct 1, 2018	Crohn's Disease
NCT02552212	Phase 3	Completed	Sep 1, 2015	May 1, 2020	Axial Spondyloarthritis
NCT02505542	Phase 3	Completed	Jul 1, 2015	Apr 1, 2019	Axial Spondyloarthrithis
NCT02365948	Phase 1	Completed	Mar 1, 2015	Aug 1, 2015	Healthy Subjects
NCT02326298	Phase 3	Completed	Dec 16, 2014	Oct 24, 2018	Psoriasis
NCT02326272	Phase 3	Completed	Dec 15, 2014	Sep 12, 2018	Psoriasis
NCT02319642	Phase 3	Completed	Nov 1, 2014	Dec 1, 2016	Rheumatoid Arthritis
NCT02154425	Phase 1	Completed	Sep 1, 2014	Jan 1, 2016	Axial Spondyloarthritis (AxSpA)
NCT02019602	Phase 1	Completed	Jan 1, 2014	Nov 1, 2016	Axial Spondyloarthritis (AxSpA)
NCT02293590	Phase 2	Completed	Nov 1, 2013	Jan 15, 2018	Rheumatoid Arthritis
NCT01443364	Approved	Completed	Dec 1, 2011	May 1, 2015	Rheumatoid Arthritis
NCT01292265	Phase 3	Terminated	Feb 1, 2011	Jan 1, 2012	Rheumatoid Arthritis
NCT01213017	Phase 3	Completed	Sep 1, 2010	Apr 1, 2012	Rheumatoid Arthritis
NCT01053559	Pre-clinical	Completed	Jan 1, 2010	Sep 1, 2013	Crohn's Disease

Competing Products

20 competing products in Axial Spondyloarthrithis

See all competitors

Product	Company	Stage	Hype Score
SUNPG1622 I dose + Placebo dose	Sun Pharmaceutical	Phase 2	27
Brodalumab + Placebo	Kyowa Kirin	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
Ixekizumab + Placebo	Eli Lilly	Phase 3	40
SHR0302 + SHR0302 placebo	Jiangsu Hengrui Medicine	Phase 3	36
SHR-1314	Jiangsu Hengrui Medicine	Phase 1	29
Upadacitinib	AbbVie	Pre-clinical	33
Adalimumab	AbbVie	Approved	35
Adalimumab + Placebo + Open-label Adalimumab	AbbVie	Phase 3	40
adalimumab + Placebo	AbbVie	Phase 3	40
Treatment	Merck	Pre-clinical	66
Golimumab	Merck	Phase 3	40
Tulisokibart + Placebo	Merck	Phase 2	42
Secukinumab 150 milligram [Cosentyx]	Novartis	Approved	39
secukinumab	Novartis	Pre-clinical	26
Secukinumab + Placebo	Novartis	Phase 3	40
Secukinumab + Placebo + Secukinumab	Novartis	Approved	47
Secukinumab + Secukinumab and Placebo	Novartis	Phase 3	40
Secukinumab/Adalimumab-Biosimilar	Novartis	Phase 3	40
Brodalumab 210 mg + Placebo	Amgen	Phase 2	27